Patients with inflammatory breast cancer tend to be younger than patients
with other types of breast cancer (the majority are 40 to 59 years old at diagnosis) and they are also somewhat more likely to be African American or pregnant at the time of diagnosis.
Triple - negative breast cancers tend to grow and spread more quickly than
most other types of breast cancer, and a lack of these receptors limits treatment options.
Further, the relationship between Myc and TXNIP is not observed
in other types of breast cancer, suggesting that it is a feature of only aggressive triple negative breast cancers and not other less aggressive breast cancer types.
TNBC is deadly because,
unlike other types of breast cancers such as estrogen receptor (ER) positive or HER2 amplified breast tumours which have effective targeted therapy, TNBC tumours do not respond to targeted therapy.
Triple - negative tumors are also more likely to spread and recur than
other types of breast cancers.
Compared to
other types of breast cancer, triple negative breast cancers are often more aggressive and have fewer treatment options.
«Triple - negative breast cancers tend to be more aggressive compared to
other types of breast cancers, and being able to predict response to therapy could greatly impact treatment decisions and patient outcomes,» says study author Shaveta Vinayak, MD, oncologist at UH Case Medical Center and Assistant Professor at Case Western Reserve University School of Medicine.
According to the Triple Negative Breast Cancer Foundation, this type of cancer can be particularly aggressive and is more likely to recur after treatment than
other types of breast cancer.
Inflammatory breast cancer tends to strike five years earlier, on average, than
other types of breast cancer, and it might not show up on a mammogram.